ClinicalTrials.gg
Active, not recruitingNCT07799025Updated Sep 2, 2026

Phase 1 Clinical Study of MWX203 Injection in Healthy Subjects

A Phase 1 interventional study of MWX203 S1 and Placebo in Healthy Volunteers, sponsored by Shanghai Minwei Biotechnology Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Shanghai Minwei Biotechnology Co., Ltd (part of Lepu Medical) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jul 2025, registered Aug 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, single ascending dose Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of MWX203 Injection in healthy Chinese subjects.

The study comprises six dose cohorts with a planned enrollment of 54 subjects. The primary endpoint is safety, assessed by adverse events (AEs), serious adverse events (SAEs), vital signs, physical examinations, laboratory tests, and 12-lead electrocardiograms. Secondary endpoints include plasma PK parameters, urinary PK parameters, and immunogenicity (anti-drug antibodies).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Shanghai Minwei Biotechnology Co., Ltd is the lead sponsor of 21 studies on the registry; 10 are open to participants now.

First submitted after Shanghai Minwei Biotechnology Co., Ltd became part of Lepu Medical.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects aged 18 to 55 years (inclusive) at the time of signing the form (ICF).
  2. Fasting serum LDL-C ≥ 2.6 mmol/L (100 mg/dL) and \< 4.1 mmol/L (158 mg/dL), and fasting triglycerides ≥ 1.1 mmol/L (100 mg/dL) and \< 5.7 mmol/L (500 mg/dL) at screening; no lipid-regulating drugs used within the past 3 months.
  3. (BMI) from 19.0 to 30.0 kg/m², inclusive, at screening; male subjects must have a body weight ≥ 50.0 kg and female subjects must have a body weight ≥ 45.0 kg.
  4. Stable diet and physical-activity habits for 4 weeks prior to screening; no major changes to diet or exercise are planned during the study, and participants will not follow any weight-loss plan.
  5. Subjects or their partners have no plans for pregnancy, sperm donation, or egg donation from the time of signing the ICF until at least 6 months after dosing, and agree to use medically-recognized, effective non-pharmacological methods throughout the study.
  6. Voluntarily participate in the study; able to read, understand, and sign the ICF before study participation; willing to comply with the study protocol and expected to complete the study.

Exclusion criteria

Exclusion Criteria:

  1. Any infectious disease within 4 weeks prior to screening (as judged by the investigator to affect the subject's ability to participate in the study).
  2. Serious trauma or major surgery (requiring general anesthesia) within 6 months prior to screening, or planned major surgery during the study.
  3. At screening, any of the following laboratory abnormalities: (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), or total > 1.5 × ; serum creatinine > 1.2 × ULN; or estimated (eGFR) \< 90 mL/min/1.73 m² (calculated using the CKD-EPI equation, Appendix 4).
  4. ≥ 450 ms (male) or ≥ 470 ms (female) at screening; or clinically-significant abnormalities on the 12-lead .
  5. > ULN.
  6. Overall atherosclerotic cardiovascular disease (ASCVD) risk assessed by the investigator as moderate or high risk at screening.
  7. Use of any liver-targeted oligonucleotide drug within 1 year prior to screening.
  8. Pregnant or lactating female subjects at screening.
  9. Difficult venous access, difficult subcutaneous injection, or intolerance to repeated venipuncture; or needle phobia or blood phobia history as judged by the investigator.
  10. Use of any over-the-counter medications, prescription medications, traditional Chinese medicine, vitamins, or health supplements within 2 weeks prior to screening or within 5 half-lives of any prior medication (whichever is longer).
  11. Receipt of any , live attenuated vaccine, or vaccines containing live viral components within 3 months prior to screening or planned vaccination during the study.
  12. Any other condition judged by the investigator to make the subject unsuitable for participation in this study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    MWX203 Cohort 1

    Escalating doses of MWX203 or matching placebo were administered via subcutaneous injection to healthy volunteers.

    Drug: MWX203 S1 · Drug: Placebo

  • Experimental
    MWX203 Cohort 2

    Escalating doses of MWX203 or matching placebo were administered via subcutaneous injection to healthy volunteers.

    Drug: Placebo · Drug: MWX203 S2

  • Experimental
    MWX203 Cohort 3

    Escalating doses of MWX203 or Matching placebo were administered via subcutaneous injection to healthy volunteers.

    Drug: Placebo · Drug: MWX203 S3

  • Experimental
    MWX203 Cohort 4

    Escalating doses of MWX203 or Matching placebo were administered via subcutaneous injection to healthy volunteers.

    Drug: Placebo · Drug: MWX203 S4

  • Experimental
    MWX203 Cohort 5

    Escalating doses of MWX203 or Matching placebo were administered via subcutaneous injection to healthy volunteers.

    Drug: Placebo · Drug: MWX203 S5

  • Experimental
    MWX203 Cohort 6

    Escalating doses of MWX203 or Matching placebo were administered via subcutaneous injection to healthy volunteers.

    Drug: Placebo · Drug: MWX203 S6

Interventions

  • DrugMWX203 S1

    administered subcutaneously (SC)

  • DrugPlacebo

    administered SC

  • DrugMWX203 S2

    administered SC.

  • DrugMWX203 S3

    administered SC.

  • DrugMWX203 S4

    administered SC.

  • DrugMWX203 S5

    administered SC.

  • DrugMWX203 S6

    administered SC.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    The incidence of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: Through study completion, for at least 85 days

Secondary outcomes

  1. Maximum Concentration (Cmax)

    Cmax of MWX203.

    Time frame: Up to 48 hours post-dose

  2. Time to Reach Maximum Concentration (Tmax)

    Tmax of MWX203.

    Time frame: Up to 48 hours post-dose

  3. Area Under the Curve From Time 0 to Last Quantifiable Time Point (AUC0-t)

    AUC0-t of MWX203.

    Time frame: Up to 48 hours post-dose

  4. Area Under the Curve From Time 0 to Infinity (AUC0-inf)

    AUC0-inf of MWX203.

    Time frame: Up to 48 hours post-dose

  5. Elimination Half-Life (t1/2)

    t1/2 of MWX203.

    Time frame: Up to 48 hours post-dose

  6. Terminal Elimination Rate Constant (λz)

    λz of MWX203.

    Time frame: Up to 48 hours post-dose

  7. Apparent Oral Clearance (CL/F)

    CL/F of MWX203.

    Time frame: Up to 48 hours post-dose]

  8. Apparent Volume of Distribution (Vd/F)

    Vd/F of MWX203.

    Time frame: Up to 48 hours post-dose

  9. Mean Residence Time (MRT)

    MRT of MWX203.

    Time frame: Up to 48 hours post-dose

  10. Cumulative Urinary Excretion (Ae)

    Ae of MWX203.

    Time frame: Up to 48 hours post-dose

  11. Fraction of Dose Excreted in Urine (Fe)

    Fe of MWX203.

    Time frame: Up to 48 hours post-dose

  12. Renal Clearance (CLr)

    CLr of MWX203.

    Time frame: Up to 48 hours post-dose

  13. Anti-Drug Antibody (ADA)

    ADA of MWX203.

    Time frame: Up to Day 85

Other outcomes

  1. Change From Baseline in Serum ANGPTL3

    Measurement of the concentration of ANGPTL3 in serum samples.

    Time frame: Through study completion, for at least 85 days

  2. Change From Baseline in Serum PCSK9

    Measurement of the concentration of PCSK9 in serum samples.

    Time frame: Up to Day 85

  3. Fasting Blood Lipid Parameters

    Lipid parameters include LDL-C, TC, TG, HDL-C, non-HDL-C, Lp (a), ApoB, VLDL-C, and ApoA1.

    Time frame: Through study completion, for at least 85 days

  4. Identification of Potential Metabolites of MWX203

    LC-TOF-MS will be used to obtain high-resolution MS and MS/MS spectra and identify the structure of major metabolites in plasma and urine following single subcutaneous MWX203 administration, so as to infer the main metabolic pathways of MWX203.

    Time frame: Up to 48 hours post-dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Mar 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Sep 2, 2026
StartActual
Jul 7, 2025
Primary completionActual
Mar 7, 2026
CompletionEst.
Jan 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07799025
Responsible party
Sponsor
First posted
Sep 2, 2026
Start date
Jul 7, 2025
Primary completion
Mar 7, 2026
Completion
Jan 2027 (estimated)
Last update
Sep 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion